| Customization: | Available |
|---|---|
| Product Name: | Rif Aximin |
| CAS No.: | 806 21-8 1-4 |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Rif aximin |
| CAS number | 806 21-8 1-4 |
| Molecular formula | C43H51N3O11 |
| Molecular weight | 785.89 |
| Appearance | White Powder |
| Purity | 99.0% |
| Description | Rif aximin is an intestinal antibiotics, is a kind of rifamycin derivatives. Features the largest in the gastrointestinal tract after oral administration is not absorbed, strong antibacterial activity, antibacterial spectrum. Compared with aminoglycoside antibiotics, the product of the Yellow Staphylococcus pyogenes gram positive aerobic bacteria on gold, Staphylococcus epidermidis and Enterococcus, highly active against gram positive anaerobic bacteria of Clostridium difficile, and aminoglycoside antibiotics against the bacterial activity is very low or very low. Rif aximin has high activity against Bacteroides, and aminoglycosides No. The adverse reaction of rif aximin is far below the aminoglycosides, it does not damage the hearing function, does not cause renal insufficiency, and can avoid the double infection. Gram positive and gram negative, aerobic and anaerobic bacteria induced acute, chronic intestinal infection syndrome; diarrhea; intestinal microflora induced diarrhea (enterocolitis, antibiotics induced enterocolitis, traveler's diarrhea), intestinal preventive medication before and after operation, hyperammonemia, portal vein system encephalitis, liver wrong game. |
| Function | Rif aximin is licensed by the U.S. Food and Drug Administration to treat traveler's diarrheacaused by E. coli. Clinical trials have shown that rif aximin is highly effective at preventing and treating traveler's diarrhea among travelers to Mexico, with few side effects and low risk of developing antibiotic resistance. It is not effective against Campylobacter jejuni, and there is no evidence of efficacy against Shigella orSalmonella species. It may be efficacious in relieving chronic functional symptoms of bloating and flatulence that are common in irritable bowel syndrome (IBS). There was recently a pilot-study done on the efficacy of rif aximin as a means of treatment for rosacea, according to the study, induced by the co-presence of small intestinal bacterial overgrowth. In the United States, rif aximin has orphan drug status for the treatment of hepatic encephalopathy. Although high-quality evidence is still lacking, rif aximin appears to be as effective as or more effective than other available treatments for hepatic encephalopathy (such as lactulose), is better tolerated, and may work faster. The drawbacks to rif aximin are increased cost and lack of robust clinical trials for HE without combination lactulose therapy. |
1.Rif aximin is highly active against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecalis in Gram-positive aerobic bacteria, Salmonella, Escherichia coli, Shigella, Yersinia enterocolitica and Coccus in Gram-negative irregular aerobic bacteria, and Bacteroides in Gram-negative anaerobic bacteria.
2.Rif aximin can effectively treat bacterial intestinal infection, hepatic encephalopathy and inflammatory bowel disease.
){kind=link}